LINEAGE CELL THERAPEUTICS IN (LCTX) Stock Fundamental Analysis

USA • NYSE Arca • NYSEARCA:LCTX • US53566P1093

1.76 USD
+0.22 (+14.29%)
At close: Feb 3, 2026
1.75 USD
-0.01 (-0.57%)
After Hours: 2/3/2026, 8:28:45 PM
Fundamental Rating

3

Taking everything into account, LCTX scores 3 out of 10 in our fundamental rating. LCTX was compared to 524 industry peers in the Biotechnology industry. While LCTX seems to be doing ok healthwise, there are quite some concerns on its profitability. LCTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year LCTX has reported negative net income.
  • LCTX had a negative operating cash flow in the past year.
  • In the past 5 years LCTX always reported negative net income.
  • In the past 5 years LCTX reported 4 times negative operating cash flow.
LCTX Yearly Net Income VS EBIT VS OCF VS FCFLCTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • LCTX has a Return On Assets (-45.06%) which is comparable to the rest of the industry.
  • The Return On Equity of LCTX (-84.55%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -45.06%
ROE -84.55%
ROIC N/A
ROA(3y)-19.65%
ROA(5y)-20.55%
ROE(3y)-31.15%
ROE(5y)-32.32%
ROIC(3y)N/A
ROIC(5y)N/A
LCTX Yearly ROA, ROE, ROICLCTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

  • With an excellent Gross Margin value of 97.55%, LCTX belongs to the best of the industry, outperforming 97.14% of the companies in the same industry.
  • In the last couple of years the Gross Margin of LCTX has grown nicely.
  • The Profit Margin and Operating Margin are not available for LCTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.77%
GM growth 5Y1.84%
LCTX Yearly Profit, Operating, Gross MarginsLCTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

More info and screens

4

2. Health

2.1 Basic Checks

  • LCTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • LCTX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for LCTX has been increased compared to 5 years ago.
  • Compared to 1 year ago, LCTX has an improved debt to assets ratio.
LCTX Yearly Shares OutstandingLCTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
LCTX Yearly Total Debt VS Total AssetsLCTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -1.92, we must say that LCTX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of LCTX (-1.92) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.00 indicates that LCTX is not too dependend on debt financing.
  • LCTX has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: LCTX outperforms 51.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.92
ROIC/WACCN/A
WACC8.93%
LCTX Yearly LT Debt VS Equity VS FCFLCTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 4.08 indicates that LCTX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.08, LCTX is in line with its industry, outperforming 49.24% of the companies in the same industry.
  • A Quick Ratio of 4.08 indicates that LCTX has no problem at all paying its short term obligations.
  • The Quick ratio of LCTX (4.08) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.08
Quick Ratio 4.08
LCTX Yearly Current Assets VS Current LiabilitesLCTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

  • LCTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -91.67%.
  • LCTX shows a small growth in Revenue. In the last year, the Revenue has grown by 6.19%.
  • LCTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.96% yearly.
EPS 1Y (TTM)-91.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
Revenue 1Y (TTM)6.19%
Revenue growth 3Y29.84%
Revenue growth 5Y21.96%
Sales Q2Q%-2.59%

3.2 Future

  • Based on estimates for the next years, LCTX will show a very strong growth in Earnings Per Share. The EPS will grow by 25.57% on average per year.
  • The Revenue is expected to grow by 60.92% on average over the next years. This is a very strong growth
EPS Next Y-211.1%
EPS Next 2Y16.07%
EPS Next 3Y6.4%
EPS Next 5Y25.57%
Revenue Next Year19.95%
Revenue Next 2Y64.1%
Revenue Next 3Y40.48%
Revenue Next 5Y60.92%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LCTX Yearly Revenue VS EstimatesLCTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
LCTX Yearly EPS VS EstimatesLCTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • LCTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LCTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LCTX Price Earnings VS Forward Price EarningsLCTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LCTX Per share dataLCTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.07%
EPS Next 3Y6.4%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for LCTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

LINEAGE CELL THERAPEUTICS IN

NYSEARCA:LCTX (2/3/2026, 8:28:45 PM)

After market: 1.75 -0.01 (-0.57%)

1.76

+0.22 (+14.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-09
Inst Owners41.2%
Inst Owner Change0.17%
Ins Owners5.39%
Ins Owner Change0.16%
Market Cap405.38M
Revenue(TTM)9.50M
Net Income(TTM)-40.91M
Analysts81.54
Price Target4.25 (141.48%)
Short Float %11.52%
Short Ratio20.74
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-65.65%
Min EPS beat(2)-152.86%
Max EPS beat(2)21.57%
EPS beat(4)2
Avg EPS beat(4)-22.86%
Min EPS beat(4)-152.86%
Max EPS beat(4)54.25%
EPS beat(8)5
Avg EPS beat(8)-2.23%
EPS beat(12)8
Avg EPS beat(12)3.98%
EPS beat(16)9
Avg EPS beat(16)-13.64%
Revenue beat(2)1
Avg Revenue beat(2)31.49%
Min Revenue beat(2)-21.11%
Max Revenue beat(2)84.09%
Revenue beat(4)3
Avg Revenue beat(4)98.73%
Min Revenue beat(4)-21.11%
Max Revenue beat(4)258.54%
Revenue beat(8)6
Avg Revenue beat(8)55.6%
Revenue beat(12)8
Avg Revenue beat(12)37.83%
Revenue beat(16)11
Avg Revenue beat(16)51.08%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-55.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)14.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 37.14
P/FCF N/A
P/OCF N/A
P/B 8.38
P/tB 67.42
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.05
BVpS0.21
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.06%
ROE -84.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.55%
FCFM N/A
ROA(3y)-19.65%
ROA(5y)-20.55%
ROE(3y)-31.15%
ROE(5y)-32.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.77%
GM growth 5Y1.84%
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 93.78%
Cap/Sales 5.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.08
Quick Ratio 4.08
Altman-Z -1.92
F-Score5
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)82.11%
Cap/Depr(5y)57.88%
Cap/Sales(3y)5.42%
Cap/Sales(5y)5.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-91.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
EPS Next Y-211.1%
EPS Next 2Y16.07%
EPS Next 3Y6.4%
EPS Next 5Y25.57%
Revenue 1Y (TTM)6.19%
Revenue growth 3Y29.84%
Revenue growth 5Y21.96%
Sales Q2Q%-2.59%
Revenue Next Year19.95%
Revenue Next 2Y64.1%
Revenue Next 3Y40.48%
Revenue Next 5Y60.92%
EBIT growth 1Y20.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-56.2%
EBIT Next 3Y2.48%
EBIT Next 5Y2.67%
FCF growth 1Y27.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.91%
OCF growth 3YN/A
OCF growth 5YN/A

LINEAGE CELL THERAPEUTICS IN / LCTX FAQ

What is the fundamental rating for LCTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to LCTX.


What is the valuation status for LCTX stock?

ChartMill assigns a valuation rating of 0 / 10 to LINEAGE CELL THERAPEUTICS IN (LCTX). This can be considered as Overvalued.


What is the profitability of LCTX stock?

LINEAGE CELL THERAPEUTICS IN (LCTX) has a profitability rating of 2 / 10.


What is the expected EPS growth for LINEAGE CELL THERAPEUTICS IN (LCTX) stock?

The Earnings per Share (EPS) of LINEAGE CELL THERAPEUTICS IN (LCTX) is expected to decline by -211.1% in the next year.